A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Lilly logo

Lilly

Status and phase

Completed
Phase 3

Conditions

Migraine

Treatments

Drug: Galcanezumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT02614287
15770
I5Q-MC-CGAJ (Other Identifier)
2015-001884-38 (EudraCT Number)

Details and patient eligibility

About

The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.

Enrollment

270 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have a diagnosis of episodic or chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1, 1.2 or 1.3) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, and migraine onset prior to age 50.
  • Prior to baseline, a history of 4 or more migraine headache days per month on average for the past 3 months.

Exclusion criteria

  • Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.
  • Current use or prior exposure to galcanezumab or another CGRP antibody.
  • Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab.
  • History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

270 participants in 2 patient groups

Galcanezumab 120 mg
Experimental group
Description:
Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
Treatment:
Drug: Galcanezumab
Galcanezumab 240 mg
Experimental group
Description:
Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
Treatment:
Drug: Galcanezumab

Trial documents
2

Trial contacts and locations

27

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems